Journal
LANCET ONCOLOGY
Volume 13, Issue 1, Pages 43-54Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(11)70293-5
Keywords
-
Categories
Funding
- Academic Radiotherapy Unit, Cancer Research UK [SP2312/021]
- Department of Health
- Cancer Research UK [C8262/A7253, CRUK/06/016]
- National Institute for Health Research
- National Health Service
- Cancer Research UK [7253, 10588] Funding Source: researchfish
Ask authors/readers for more resources
Background Prostate cancer might have high radiation-fraction sensitivity, implying a therapeutic advantage of hypofractionated treatment. We present a pre-planned preliminary safety analysis of side-effects in stages 1 and 2 of a randomised trial comparing standard and hypofractionated radiotherapy. Methods We did a multicentre, randomised study and recruited men with localised prostate cancer between Oct 18, 2002, and Aug 12, 2006, at 11 UK centres. Patients were randomly assigned in a 1:1:1 ratio to receive conventional or hypofractionated high-dose intensity-modulated radio therapy, and all were given with 3-6 months of neoadjuvant androgen suppression. Computer-generated random permuted blocks were used, with risk of seminal vesicle involvement and radiotherapy-treatment centre as stratification factors. The conventional schedule was 37 fractions of 2 Gy to a total of 74 Gy. The two hypofractionated schedules involved 3 Gy treatments given in either 20 fractions to a total of 60 Gy, or 19 fractions to a total of 57 Gy. The primary endpoint was proportion of patients with grade 2 or worse toxicity at 2 years on the Radiation Therapy Oncology Group (RTOG) scale. The primary analysis included all patients who had received at least one fraction of radiotherapy and completed a 2 year assessment. Treatment allocation was not masked and clinicians were not blinded. Stage 3 of this trial completed the planned recruitment in June, 2011. This study is registered, number ISRCTN97182923. Findings 153 men recruited to stages 1 and 2 were randomly assigned to receive conventional treatment of 74 Gy, 153 to receive 60 Gy, and 151 to receive 57 Gy. With 50.5 months median follow-up (IQR 43.5-61.3), six (4.3%; 95% CI 1.6-9.2) of 138 men in the 74 Gy group had bowel toxicity of grade 2 or worse on the RTOG scale at 2 years, as did five (3.6%; 1.2-8.3) of 137 men in the 60 Gy group, and two (1.4%; 0.2-5.0) of 143 men in the 57 Gy group. For bladder toxicities, three (2.2%; 0.5-6.2) of 138 men, three (2.2%; 0.5-6.3) of 137, and none (0.0%; 97.5% CI 0.0-2.6) of 143 had scores of grade 2 or worse on the RTOG scale at 2 years. Interpretation Hypofractionated high-dose radiotherapy seems equally well tolerated as conventionally fractionated treatment at 2 years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available